Streetbeat News

RLMD

Relmada Therapeutics, Inc.

https://www.relmada.com

Industry

Biotechnology

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

Open

0.36

Mkt cap

11M

Volume

842K

High

0.37

P/E Ratio

-0.13

52-wk high

7.22

Low

0.35

Div yield

N/A

52-wk low

0.35

Relmada Therapeutics announced that the Phase 3 Reliance II trial for their CNS drug is deemed futile by the Data Monitoring Committee, indicating it is unlikely to meet its primary efficacy endpoint. Despite this setback, Relmada will focus on developing REL-P11 for metabolic disease and has $54.1 million in cash reserves.

Portfolio Pulse from

December 04, 2024 | 12:45 pm

Relmada Therapeutics has started a Phase 1 study for REL-P11, a psilocybin formulation aimed at treating metabolic diseases. The study will assess safety and pharmacokinetics in different weight groups, with a Phase 2a study planned for 2025 if results are positive.

Portfolio Pulse from

November 14, 2024 | 12:45 pm

Relmada Therapeutics, Inc. (RLMD) held its Q3 2024 earnings call on November 7, 2024. The call featured company executives discussing financial results and was attended by analysts, including Andrew Tsai from Jefferies.

Portfolio Pulse from

November 10, 2024 | 3:00 pm

Relmada Therapeutics reported its Q3 2024 financial results, highlighting a cash position of $54.1 million, which supports operations into 2025. Key developments include a Phase 3 interim analysis for REL-1017 and a Phase 1 study for REL-P11, both expected by the end of 2024.

Portfolio Pulse from

November 07, 2024 | 9:45 pm

Relmada Therapeutics has released its third-quarter 2024 financial results and provided a business update. A significant upcoming event is the pre-planned Phase 3 Reliance II interim analysis for REL-1017, expected by the end of 2024, which could be a crucial de-risking event for the company.

Portfolio Pulse from

November 07, 2024 | 9:30 pm

Relmada Therapeutics will release its Q3 2024 financial results on November 7, 2024, and will host a conference call to discuss its business progress and financial performance.

Portfolio Pulse from

November 05, 2024 | 12:30 pm

Relmada Therapeutics shares surged after Jefferies upgraded the stock from Hold to Buy and increased its price target from $3.5 to $13.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 12:51 pm

Jefferies analyst Andrew Tsai has upgraded Relmada Therapeutics from Hold to Buy and increased the price target from $3.5 to $13.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 12:46 pm

Relmada Therapeutics has filed for a mixed shelf offering of up to $250 million, according to an SEC filing. This move allows the company to raise capital through the sale of various securities, which could include common stock, preferred stock, debt securities, and warrants.

Portfolio Pulse from Benzinga Newsdesk

August 30, 2024 | 8:30 pm

Relmada Therapeutics shares are trading lower following the company's Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 4:50 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.